All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The Lymphoma Hub was delighted to host an interview with Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What was new in aggressive non-Hodgkin lymphoma at this year's American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) virtual meetings?
This interview outlines three main fields of development:
What was new in aggressive NHL at ASCO and EHA 2020?
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox